Acandis's Aperio Hybrid Stroke Thrombectomy Device Approved in Europe
June 5, 2019—Acandis GmbH announced that it has received European CE Mark approval for its Aperio hybrid thrombectomy device, which is intended for restoration of arterial flow in patients diagnosed with ischemic stroke caused by large intracranial vascular occlusion. Acandis, which is based in Pforzheim, Germany, is focused on neurointerventional devices for the prevention and treatment of strokes.
The Aperio device is the new generation of the Acandis stent retriever. Aperio's visibility, vessel wall apposition, and expansion into the clot provide for efficient clot retention and fast flow restoration.
According to the company, the device combines a hybrid cell design with a new visibility concept for more safety and control. Additionally, radiopaque DFT wires allow full-length visibility of the device for precise alignment and permanent control during the procedure.
The Aperio hybrid thrombectomy device is suitable for vessel diameters from 1.5 to 5.5 mm and can be delivered through common 0.021-inch microcatheters, stated Acandis.